On March 26, 2026, a meeting of the interdisciplinary Advisory Board in the fields of allergology, otolaryngology, and pediatrics titled “Leukotriene receptor antagonists in the treatment of respiratory allergy” was held in Moscow. Allergic rhinitis is a common chronic non-infectious disease of the upper respiratory tract, characterized by symptoms that significantly impair quality of life, sleep, and work productivity. Allergic rhinitis is frequently associated with comorbid conditions — such as allergic conjunctivitis, bronchial asthma, and adenotonsillar hypertrophy — and represents a significant risk factor for the complicated course of sinusitis. Latest-generation antihistamines and intranasal glucocorticoids are the main classes of drugs with a compelling evidence base regarding their efficacy and safety in allergic rhinitis. Despite this, more than half of all patients experience uncontrolled disease progression. One of the key challenges in achieving allergic rhinitis control is poor adherence to therapy caused by various factors, the most frequent of which include inconvenient administration (both the route and the dosing regimen), side effects, and steroidophobia. Another challenge stems from intranasal anatomical features (such as a deviated nasal septum or concha bullosa/hyperpneumatization of the middle turbinate), which can impede the adequate distribution of therapeutic concentrations of intranasal drugs within the nasal cavity. Leukotriene receptor antagonists suppress inflammation of the nasal and bronchial mucosa, are effective against nasal congestion and nighttime symptoms, and can be prescribed as monotherapy or in combination with other drugs. Prescribing leukotriene receptor antagonists to patients with comorbid allergic rhinitis and bronchial asthma allows for the control of symptoms of both diseases, reduces medication burden, and prevents polypharmacy. Fixed-dose combinations (leukotriene receptor antagonists + antihistamines), which possess synergistic and complementary actions, offer advantages over monotherapy by potentiating the therapeutic effect and improving treatment adherence. When discussing the safety profile of montelukast, including its use in a fixed-dose combination with levocetirizine, the Advisory Board reached a consensus that neuropsychiatric adverse events associated with montelukast are extremely rare, and there is no direct drug-drug interaction between montelukast and levocetirizine. It was noted, that patients with allergic rhinitis frequently present with baseline psycho-emotional disturbances related to the disease. Given the rare nature of these adverse events, the safety profile of the fixed-dose combination of montelukast and levocetirizine was recognized as favorable, and the potential benefit of this combination therapy was considered high. The prescription of the fixed-dose combination of montelukast 10 mg and levocetirizine 5 mg (Montral ML) aligns with Russian federal clinical guidelines for allergic rhinitis and is recommended at any treatment step, including as initial therapy for seasonal or perennial allergic rhinitis, especially in cases of severe nasal congestion and/or co-occurrence with bronchial asthma.